ClinicalTrials.gg
CompletedNCT01506375Updated May 26, 2014

Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant

A Phase 2 interventional study of gpASIT+TM and gpASIT+TM + adjuvant in Hay Fever, sponsored by BioTech Tools S.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2014-05-26.

Sponsored by BioTech Tools S.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Rhinitis, Allergic, Seasonal with a site in Belgium — 2 open to participants now, 2 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · Belgium.

Enrollment
10th of 10
24 · median 147
Started
2011
the only one that year
Phase 2
3 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
4 of 11
BioTech Tools S.A.

Among the 11 studies in Rhinitis, Allergic, Seasonal with a site in Belgium, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2011, is one of 3 in phase 2, and was the 4th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

2 of the 11 studies in Rhinitis, Allergic, Seasonal with a site in Belgium are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Rhinitis, Allergic, Seasonal with a site in Belgium, or all of them as a file.
02

Study summary

The aim of the study is to compare the safety, clinical tolerability, immunogenicity and efficacy of gpASIT+TM (grass pollen peptides) alone and combined with an immunoregulating adjuvant, in a short course administration (5 injections over 4 weeks).

03

Conditions studied

  • Hay Fever

Keywords

  • seasonal allergic rhinoconjunctivitis
  • grass pollen
  • allergen specific immunotherapy
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has given written
  • Age between 18 and 50 years
  • The subjects are in good physical and mental health according to his/her medical history, vital signs, and clinical status
  • Male or non-pregnant, non-lactating female
  • Females unable to bear children must have documentation of such in the CRF (i.e. tubule ligation, hysterectomy, or (defined as a minimum of one year since the last menstrual period))
  • Allergy diagnosis:

    • A medical history of moderate to severe seasonal allergic rhinoconjunctivitis (SAR) during the grass pollen season during at least the two previous years
    • A positive skin prick test (wheal diameter ≥ 3 mm) to grass-pollen mixture
    • Specific IgE against grass pollen (IgE > 0.7 kU/l) [using recombinant mixture of rPhl p1 and rPhl p5b Phleum pratense (g213)]
  • Subjects never treated by immunotherapy or subjects for whom the immunotherapy ended at December 31, 2009 and who had as well moderate to severe symptoms in the two previous years (2010 and 2011)

Exclusion criteria

Exclusion Criteria:

  • Subjects with current immunotherapy and subjects who underwent a previous immunotherapy within the last 2 years
  • Participation in another clinical trial and/or treatment with an experimental drug within the last 3 months
  • A history of to the of products
  • Subjects with perennial asthma (regular intake of inhaled outside the pollen season: consumption on a daily base or patients who are taking a reliever more than twice a week)
  • Subjects with severe seasonal asthma requiring long acting beta agonist AND inhaled steroid treatment
  • Subjects with a VC \< 80% and a \< 70% of predicted value at the screening visit
  • Subjects symptomatic to perennial inhalant allergens who should need antihistamine drug or systemic corticoids to relieve allergic symptoms during the treatment period
  • Subjects with documented evidence of chronic sinusitis (as determined by Investigator)
  • Subjects with rhinitis medicamentosa, non-specific rhinitis (to food dye, preservative agent...)
  • Subjects with a history of renal disease or chronic hepatic disease
  • Subject with malignant disease, disease
  • Any chronic disease, which may impair the subject's ability to participate in the trial
  • Subjects requiring beta-blockers medication
  • Chronic use of concomitant medications that would affect assessment of the effectiveness of the trial medication (e.g. tricyclic antidepressants)
  • Regular consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 4 weeks preceding the trial (screening visit)
  • Any consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 1 week preceding the trial (screening visit)
  • Subject with febrile illness (> 37.5°C, oral)
  • A known positive serology for -1/2, or
  • Subjects that are by medication or illness, have received a vaccine, corticoids or immunosuppressive medications within 1 month before trial entry
  • Receipt of blood or a blood derivative in the past 6 months preceding trial entry
  • Female subjects who are pregnant, lactating, or of and not protected from pregnancy by a sufficiently reliable method
  • Any condition which could be incompatible with protocol understanding and compliance
  • Subjects who have forfeited their freedom by administrative or legal award or who are under guardianship
  • Unreliable subjects including non-compliant subjects, subjects with known alcoholism or drug abuse or with a history of a serious psychiatric disorder as well as subjects unwilling to give or to abide by the requirements of the protocol
  • Subjects without means of contacting the Investigator rapidly in case of emergency, or not able to be contacted rapidly by the Investigator
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    gpASIT

    grass pollen peptides alone

    Biological: gpASIT+TM

  • Experimental
    gpASIT/adjuvant

    grass pollen peptides + adjuvant

    Biological: gpASIT+TM + adjuvant

Interventions

  • BiologicalgpASIT+TM

    Drug page: gpASIT+

    1 subcutaneous injection every 7 days during 29 days

  • BiologicalgpASIT+TM + adjuvant

    Drug page: Adjuvant

    1 subcutaneous injection every 7 days during 29 days

06

What researchers measure

Primary outcomes

  1. Safety of the treatment

    Safety will be evaluated by the following parameters: general physical status, vital signs, haematological parameters, general biochemical parameters, solicited local adverse events, all (serious) adverse events, immunological analysis (total IgG and IgE), inflammatory parameters (CRP) and anti-adjuvant mmunoglobulins.

    Time frame: up to the end of the grass pollen season

  2. Clinical tolerability of the treatment

    The clinical tolerability will by assessed through the solicited local adverse events, all (serious) adverse events and the investigator and subject opinion.

    Time frame: Duration of treatment period (4 weeks)

Secondary outcomes

  1. Impact of gpASIT+TM with or without adjuvant on the immunological status of the subjects.

    The following parameters will be assessed: allergen-specific immunoglobulins and blocking antibodies.

    Time frame: up to 1 year after the start of treatment

  2. Impact of gpASIT+TM with or without adjuvant on the grass pollen allergic symptoms of the subjects.

    The following parameters will be recorded: symptom and rescue medication scores (diary cards), Quality-of-Life (RQLQ(S)).

    Time frame: During the pollen season

  3. Long-term follow-up of the patients

    Safety parameters will be: immunological analysis (Total IgG and IgE), inflammatory parameters (CRP), DnaK-specific immunoglobulins and SAEs. Immunogenicity parameters will be: evolution of grass pollen specific immunoglobulins and of blocking antibodies.

    Time frame: 1 year after the start of treatment

07

Study locations

1 site
  • Universitaire Ziekenhuis van Leuven
    Leuven, 3000, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jan 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2011
First posted
Jan 10, 2012
Start
Nov 2011
Primary completionActual
Jan 2013
CompletionActual
Apr 2013
Last update
May 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01506375
Lead sponsor
BioTech Tools S.A.
Responsible party
Sponsor
First posted
Jan 10, 2012
Start date
Nov 2011
Primary completion
Jan 2013
Completion
Apr 2013
Last update
May 26, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: gpASIT+ · Adjuvant

Start the discussion